Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Huang

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
International Journal of Antimicrobial Agents|May 22, 2018
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infectionsDavid B Huang, G Ralph Corey, Thomas L Holland, et al.
Journal of Medical Microbiology|March 21, 2020
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infectionsStephanie Noviello, G Ralph Corey, Thomas L Holland, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 28, 2017
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1David B Huang, William O'Riordan, J Scott Overcash, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2018
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)Thomas L Holland, William O'Riordan, Alison McManus, et al.
The Journal of Infectious Diseases|November 30, 2013
Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremiaRaymond Schuch, Han M Lee, Brent C Schneider, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 27, 2007
Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide aloneHerbert L Dupont, Zhi-Dong Jiang, Jaime Belkind-Gerson, et al.
Plos One|September 16, 2022
Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug classDavid B Huang, Kimberly M Brothers, Jonathan B Mandell, et al.
Infectious Diseases and Therapy|January 27, 2020
A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure InfectionsSarah C J Jorgensen, Kyle P Murray, Abdalhamid M Lagnf, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
International Journal of Antimicrobial Agents|May 22, 2018
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infectionsDavid B Huang, G Ralph Corey, Thomas L Holland, et al.
Journal of Medical Microbiology|March 21, 2020
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infectionsStephanie Noviello, G Ralph Corey, Thomas L Holland, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 28, 2017
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1David B Huang, William O'Riordan, J Scott Overcash, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2018
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)Thomas L Holland, William O'Riordan, Alison McManus, et al.
The Journal of Infectious Diseases|November 30, 2013
Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremiaRaymond Schuch, Han M Lee, Brent C Schneider, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 27, 2007
Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide aloneHerbert L Dupont, Zhi-Dong Jiang, Jaime Belkind-Gerson, et al.
Plos One|September 16, 2022
Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug classDavid B Huang, Kimberly M Brothers, Jonathan B Mandell, et al.
Infectious Diseases and Therapy|January 27, 2020
A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure InfectionsSarah C J Jorgensen, Kyle P Murray, Abdalhamid M Lagnf, et al.
Pageof 9